Do residual arteriovenous fistulae after in situ saphenous vein bypass grafting influence patency?  by Lundell, Anders & Nyborg, Kerstin
Since its introduction in 1962, in situ saphenous
vein bypass grafting for leg ischemia has attained
widespread acceptance.1,2 The benefits of the in situ
bypass graft include less size disparity between graft
and artery, better use of the vein, and no disruption
of the nutrient vasa vasorum.3 The grafting is, how-
ever, often necessary to detect, with preoperative
vein mapping, intraoperative angioscopy, or angiog-
raphy, the saphenous vein side branches to occlude
them during surgery. Some side branches persist as
residual arteriovenous fistulae (AVF) and may influ-
ence patency, especially if blood is shunted to the
deep venous system.4-6 Hemodynamically significant
AVF necessitate revision, which is a time-consuming
and costly procedure.7 The question therefore is
whether it is necessary to occlude all residual AVF
after in situ bypass grafting. This is of a particular
importance when minimally invasive and semi-
closed surgical techniques are used. The purpose of
this study was to evaluate the natural history of
residual AVF and to investigate the possible hemo-
dynamic significance in relation to in situ saphenous
vein bypass graft patency.
MATERIALS AND METHODS
A surveillance program after femoropopliteal/
femorocrural reconstruction has been used at our
institution since January 1, 1994. Surveillance data
are collected prospectively and entered in a comput-
er-based registry. The data include sex, age, presence
of diabetes, type of operation, graft material, indica-
tion for operation, time to revision, occlusion,
amputation or to death, ankle brachial index, num-
ber of residual AVF, and graft hemodynamics. The
patients in this study underwent femoropopliteal or
femorocrural in situ saphenous vein bypass grafting
between January 1, 1994, and December 31, 1996.
Preoperative vein mapping was not used on a rou-
tine basis.
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Purpose: The purpose of this study was to evaluate the influence on patency of residual
arteriovenous fistulae (AVF) after in situ saphenous vein bypass grafting.
Methods: Between January 1, 1994, and December 31, 1996, 98 in situ saphenous vein
bypass grafting procedures were performed in 94 patients. Patency was evaluated with
duplex scanning after operation and at 1, 3, 6, 9, and 12 months. 
Results: The indications for operation were intermittent claudication in two patients and
critical leg ischemia in 92 patients. Two above-knee and 48 below-knee femoropopliteal
and 48 femorocrural in situ saphenous vein bypass grafting procedures were performed.
The median follow-up period was 9 months (range, 1.5 to 12.5 months). There were no
residual AVF in 45 veins (44%; group 1), but 110 residual AVF were found in 53 veins
(56%; group 2). In group 2, 36 AVF in 18 veins were surgically or radiologically occlud-
ed mainly as a result of a flow velocity decrease distal to the AVF, but the remaining 74
AVF were treated conservatively. The 1-year cumulative primary patency rates were 68%
in group 1 and 74% in group 2 (log-rank test, 0.47; degree of freedom = 1; P = .52).
The 1-year cumulative assisted primary patency rates were 68% in group 1 and 81% in
group 2 (log-rank test, 2.19; degree of freedom = 1; P = .14).
Conclusion: Residual AVF after in situ bypass grafting without influence on bypass graft
hemodynamics do not compromise patency and thrombose spontaneously. (J Vasc Surg
1999;30:99-105.)
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Thrombosis prophylaxis with one daily subcuta-
neous injection of 40 mg of Enoxaparin (Rhone-
Poulenc Rohrer, Collegville, Pa) was started the day
before surgery and continued for the duration of the
hospital stay. The patients underwent a three-dose
antibiotic prophylaxis treatment with 2 g intra-
venously of cloxacillin sodium (ASTRA, Stockholm,
Sweden) with a 12-hour interval beginning at the
commencement of surgery. The surgery was per-
formed without angioscopy or semi-closed AVF lig-
ature. The saphenous vein was divided at the deep
femoral junction. Before arterial clamping, sodium
heparin (5000 units; Pharmacia-Upjohn, Stock-
holm, Sweden) was given intravenously. The proxi-
mal anastomosis was made end to side at the origin
of the deep femoral artery with a running CV 6
Gore-Tex suture (WL Gore Associates Inc, Flagstaff,
Ariz). After the completion of the proximal anasto-
mosis restoration of blood flow, a LeMaitre,
(Vascutech Inc, Burlington, Mass) 2.5-mm to 4-mm
fixed diameter valvulotome was introduced through
the distal vein end for valve disruption. When a pul-
satile flow through the vein was accomplished, the
distal anastomosis was completed end to side with a
CV 7 Gore-Tex running suture. AVF that were
detected during operation were ligated. The fistulae
were identified with flow measurements with a tran-
sit time ultrasound volume flow meter Transonic TC
107 (Transonic Inc, Ithaca, NY) or a Cardiomed
CM-1005 (Cardiomed A/S, Horten, Norway).
After restoration of blood flow, a 5-mm or 6-mm
flow probe was placed over the saphenous vein at the
proximal anastomosis along the length axis of the
vein. To achieve a good ultrasound signal, the space
between the probe and the vein was filled with
heparinized saline solution. The vein distal to the
probe was occluded with digital compression. Flow
through the vein was unaffected or only slightly
reduced when an AVF was present between the site
of the compression and the probe but was decreased
to zero when no AVF was present. The site of the
AVF was marked, a small incision was made, and the
AVF was ligated. Fistulae with flows of less than 10
mL/min were not ligated. Completion angiography
was used to detect missed AVF and to assess paten-
cy, the anastomoses, and the outflow tract before
wound closure.
Bypass graft function was followed through the
surveillance program. The patients underwent eval-
uation at the vascular clinic with a duplex scan at 1
or 2 days after surgery and at 1, 3, 6, 9, and 12
months thereafter.
The duplex scan examinations were performed
with an Acuson 128 XP/10 duplex scanner (Acuson
Inc, Mountain View, Calif) that was equipped with a
real-time linear array multifrequency sector trans-
ducer with 3.5-MHz and 5-MHz settings to gener-
ate a B-mode image of the vessels and the pulsed
Doppler scan signals. The Doppler scan signals were
analyzed under a Doppler angle set as near as possi-
ble to 60 degrees. For any area in which stenosis was
suspected, Doppler scan spectra were recorded prox-
imal to, at, and just distal to the stenosis. The whole
length of the graft, including the anastomoses, was
examined. Residual AVF were identified, and the
peak flow velocity proximal and distal to the AVF
was recorded. The Doppler scan signal parameters
recorded were the peak systolic flow velocity (PSV;
in cm/s), the PSV ratio (PSV proximal to the AVF
divided by PSV distal to the AVF), and the spectral
waveform. Spectral analysis was made with visual
interpretation of the Doppler scan velocity spec-
trum. A PSV of more than 2 m/s or a ratio more
than 2.0 was defined as a stenosis >50%.8,9 A similar
index was used for residual AVF. An AVF/PSV ratio
(PSV proximal/PSV distal to the AVF) of more than
1 proximal was considered to indicate an AVF that
adversely influenced in situ vein hemodynamics
through a shunting of blood to the deep venous sys-
tem.10 Occlusive superficial phlebitis as a result of an
unligated branch was not found to be an indication
for ligature. In addition to the duplex scan, the ankle
brachial ratio (ABI) was calculated and a clinical
assessment of graft function was made. The bypass
grafts thereafter were divided in two groups on the
basis of the presence or the absence of residual AVF
at the postoperative duplex scan control, without
AVF (group 1) or with one or more residual AVF
(group 2). A failing graft was suspected during fol-
low-up provided that duplex scanning indicated a
graft or anastomosis stenosis of more than 50% or if
the ABI decreased more than 0.15 between two
controls. The diagnosis was verified with control
angiography.
Primary patency rates (uninterrupted patency
without intervention) and assisted primary patency
rates (uninterrupted patency with bypass graft revi-
sion) were calculated for both groups. Patency was
defined according to the Society for Vascular
Surgery and International Society for Cardiovascular
Surgery criteria.11 Values were median and
interquartile range. A StatView 4.5 statistics pro-
gram for Macintosh (SAS Institute, Cary, NC) was
used for the statistical analyses. The Kaplan-Meier
method and log-rank tests were used for the analysis
of the survival data. The Mann-Whitney test was
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used for the comparison between the groups. A P
value of less than .05 was considered significant.
RESULTS
From January 1, 1994, through December 31,
1996, 94 patients underwent 98 femoropopliteal or
femorocrural in situ saphenous vein bypass grafting
procedures. There were 59 men, and the median age
was 76 years (range, 70 to 82 years). Diabetes, type 1
or 2, was present in 34 patients (36%). Indication was
critical leg ischemia in all the patients but two (inter-
mittent claudication, one in each group). There were
50 femoropopliteal (two above-knee and 48 below-
knee) reconstructions and 48 femorocrural recon-
structions. There were no differences with regard to
sex distribution, age, presence of diabetes, indication
for surgery, and type of reconstruction between the
groups, although the portion of femorocrural recon-
structions in group 2 was higher as compared with
group 1 (Table I). The 30-day mortality rate was 4.4%
(four patients). Eight veins occluded during the 30-
day postoperative period. The median follow-up peri-
od was 9 months (range, 1.5 to 12.5 months). No
AVF were detected in 45 veins (group 1). At the 1-
month follow-up examination, one residual AVF was
identified in three of these 45 veins (7%). These AVF
thrombosed spontaneously.
A total of 110 residual AVF were found in 53
veins (group 2). There were 36 ligatures or coilings
made on 46 identified AVF in 18 of the 53 veins
(Table II). AVF in four veins had to be ligated in two
separate procedures. The indication for revision was
an AVF/PSV ratio that exceeded 1 in 14 veins.
Residual AVF (n = 9) in four veins were revised,
although blood flow velocity was unaffected and no
leg swelling was present. This was done at the dis-
cretion of the surgeon. ABI was unaffected in all but
one of the 18 veins where the postoperative ABI was
low in spite of a patent graft. In addition to an
AVF/PSV ratio, more than one low ABI was per-
ceived as a steal phenomenon from a significant
AVF. After AVF ligation, ABI was doubled. A
notable leg edema occurred in four extremities
where residual AVF were ligated. Of the remaining
74 AVF, 73 thrombosed spontaneously within 12
months (Tables III and IV). Seven of the veins in
group 2 and three of the veins in group 1 necessi-
tated additional revisions as a result of stenosis of the
inflow vessel (n = 1), the proximal anastomosis (n =
2), the distal anastomosis (n = 4), the saphenous
vein (n = 2), and the residual valve leaflets (n = 1).
One patient in group 2 did not want to participate
in the surveillance program after discharge and was
considered lost to follow-up examination.
The 1-year cumulative primary patency rates
were 68% for group 1 and 74% for group 2 (log-rank
test, 0.52; degree of freedom = 1; P = .52). The 1-
year assisted primary patency rates were 68% for
group 1 and 81% for group 2 (log-rank test, 2.19;
degree of freedom = 1; P = .14; Fig 1).
DISCUSSION
Since the introduction of the in situ bypass graft,
controversy has surrounded the issue of whether or
not residual AVF influence graft patency.12 Residual
AVF may divert blood from the bypass graft to the
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Table I. Risk factors, indication for surgery, and type of reconstruction
Group 1 Group 2
No AVF (n = 45) ‡ 1 AVF (n = 53)
Sex 28 M, 17 F 33 M, 20 F
Median age (years) 76 (range, 70 to 81) 76 (range, 70 to 83)
Diabetes 15 (34%) 21 (39%)
Intermittent claudication 1 1
Rest pain 14 22
Ischemic ulcer 18 16
Gangrene 9 12
Popliteal aneurysm 3 2
Fempop AK 2 0
Fempop BK 26 22
Femorocrural 17 31
Preoperative ABI 0.54 (range, 0.17 to 0.67) 0.36 (range, 0.1 to 0.5)
Postoperative ABI 0.73 (range, 0.61 to 0.96) 0.86 (range, 0.69 to 1)
AVF, Arteriovenous fistulae; AK, above knee; BK, below knee; ABI, ankle brachial ratio.
The groups were similar with regard to risk factors and indication. There were numerically more femorocrural reconstructions in group
2 as compared with group 1.
deep venous system, thus diminishing the amount
that reaches the distal arterial bed, which could
influence patency.6
In the present study, neither primary nor assisted
primary patency rates differed between the groups.
This was even more notable because the portion of
femorocrural reconstructions was higher in group 2
as compared with group 1.
To identify AVF during operation, we used ultra-
sound volume blood flow measurements and com-
pletion angiography. Flow measurements, either with
a volume flow meter or duplex scanning, allowed an
estimation of the flow through the AVF, thus verify-
ing a hemodynamically significant lesion.12
This method was discovered to be equally effec-
tive as the “closed” in situ bypass grafting technique,
in which perioperative angiography was used.13 A
further advantage of the method was its lack of com-
plexity, which almost eliminated the learning curve.
Angioscopy with endovascular side branch occlu-
sion during in situ bypass grafting has been success-
fully used to occlude AVF.14 The technique allows
the surgeon to occlude AVF from within the saphe-
nous vein without making separate skin incisions,
thereby reducing the risk for wound complica-
tions.15 The hemodynamic significance of a poten-
tial AVF cannot, however, be estimated with
angioscopy, and an unnecessarily high number of
AVF may, as a consequence, be occluded.
Our data did not support the belief that all resid-
ual AVF should be ligated.16 In patients in group 2,
residual AVF without influence on flow velocity
thrombosed spontaneously within 1 year. It is, how-
ever, of interest to note that, in three bypass grafts
(7%) with no detected AVF at the postoperative con-
trol, one AVF was found after 1 month. These AVF
thrombosed spontaneously during the follow-up
period. Small AVF that remained closed during
operation apparently opened during the first postop-
erative month, possibly as the result of an increase in
peripheral resistance. This increase may lead to a
diversion of blood through AVF seen at the 1-
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Table II. Revised AVF
Time Assisted
to AVF primary PSV (m/s)
Patient ligature/ patency proximal PSV No. of AVF
no. Procedure coiling (days) (days) to AVF ratio (revised) Comment
1 crural 3+16 722 2 2 5 (4) ligature
2 crural 5 413 2.5 1.4 2 (1) ligature
3 crural 6 361 3 3 4 (1) ligature
4 below knee 7 34 1 1 2 (2) ligature
5 crural 7 813 0.8 1.6 1 (1) ligature, ABI increase
0.4 to 0.75
6 below knee 7 26 (occluded) 2.6 5.3 2 (1) ligature
7 below knee 7 368 1.1 2.1 2 (2) ligature
8 crural 8 46 4 1 3 (3) ligature, PTA distal
anastomosis
9 crural 13+103 1024 3 3 3 (3) coiling, PTA graft
stenosis
10 crural 35 368 1 1 3 (1) ligature
11 below knee 36 508 1.8 4.2 2 (1) ligature
12 crural 51+227 389 2.8 2 4 (4) ligature, PTA
proximal anastomosis
13 crural 56 371 0.6 1.5 3 (3) ligature
14 below knee 71+296 368 1 1 4 (3) ligature
15 below knee 78 392 2 2 1 (1) coiling, PTA proximal
anastomosis
16 below knee 191 464 0.7 1.5 2 (2) coiling, PTA and stent
iliac artery
17 crural 211 1677 1.9 1.9 2 (2) ligature, patch distal
anastomosis, PTA
· 3
18 crural 306 1162 2 1.8 1 (1) ligature, resection of
valve leaflets
Median (range) 12 380 1.9 1.8 2 (2)
(7-78) (361-469) (1.0-3.0) (1.5-3.0) (1-2[3])
AVF, Arteriovenous fistulae; PSV, peak systolic flow velocity; ABI, ankle brachial ratio; PTA, percutaneous transluminal angioplasty.
The largest proportion of revisions were made during the first 30 postoperative days. Residual arteriovenous fistulae in four veins were
ligated/coiled in two separate procedures. 
month control but not in the immediate postopera-
tive period.17-19
Operative intervention for residual AVF in our
study occurred in 18 of 98 patent grafts (18%). The
revision rate was similar to that reported by van Dijk
et al20 (20%) but higher than that reported by
Rosenthal et al21 (6%). The difference seems to be a
result of the use of intraoperative angioscopy, which
allows better identification of all venous side branch-
es and thus their occlusion.
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Table III. Conservative treatment of residual AVF, group 2
Assisted
Time to primary
Patient revision patency PSV PSV No. of
no. Procedure (days) (days) (m/s) ratio AVF Comment
1 crural 1 (occluded) 1 0.3 1 1
2 crural 1 697 1.9 1.6 1 Patch distal
anastomosis
3 crural 6 (occluded) 6 1.2 4 1
4 below knee 6 6 1 1 2 Lost to follow-up
5 crural 19 19 1 1 2
6 crural 22 22 2.1 1 2
7 crural 33 33 1 1 3
8 crural 49 49 0.7 1 1
9 crural 51 51 1 1 3
10 crural 77 77 1.6 1 1
11 crural 79 79 1 10 1
12 crural 89 89 2.2 1 1
13 crural 130 130 0.3 3 4
14 below knee 140 274 2.8 1 1 Revision with ePTFE
15 crural 188 188 1 1 1
16 below knee 190 1100 1 1 1 PTA distal
anastomosis
17 crural 248 248 1 1 1
18 crural 272 272 4 1 4
19 crural 274 274 1 1 2
20 crural 342 342 2.5 1 2
21 below knee 360 360 1 0.7 3
22 below knee 363 363 1.6 3.8 2
23 below knee 363 363 1.3 1 3
24 below knee 365 365 1 1 1
25 below knee 374 374 1.8 1 3
26 below knee 379 379 1.1 1.6 1
27 below knee 381 381 1.2 1 2
28 below knee 384 384 1 1 1
29 below knee 392 392 2.2 1 2
30 crural 397 397 2 1 1
31 below knee 454 454 1.7 1 3
32 crural 586 762 1 1.3 1 PTA of graft stenosis
33 below knee 750 750 1 1 2
34 below knee 771 771 1 1 2
35 below knee 783 783 0.6 1 2
Median 274 342 1.0 1.0 2
(57-381) (78-391) (1.0-1.8) (1.0-1.0) (1-2)
PSV, Peak systolic flow velocity; AVF, arteriovenous fistulae; ePTFE, expanded polytetrafluoroethylene; PTA, percutaneous transluminal
angioplasty.
One patient was lost to follow-up examination.
Table IV. Veins with residual AVF during follow-up, group 2
Postoperative 1 month 3 months 6 months 9 months 12 months
53/53 27/47 14/39 7/38 3/36 1/27
(100%) (57%) (36%) (18%) (8%) (4%)
After 1 year, all but one of the not ligated/coiled AVF thrombosed spontaneously. Percentage of veins with patent residual AVF during
follow-up, group 2.
A weakness of the study was that not all residual
AVF were treated conservatively. Furthermore, nine
residual AVF in four veins were ligated in spite of the
fact that our criteria for a hemodynamically signifi-
cant AVF were not met. Those AVF would probably
have thrombosed spontaneously had they been
treated conservatively. Whether or not a noninter-
ventional approach would have led to a spontaneous
thrombosis of all residual AVF, including those that
severely influenced graft hemodynamics, cannot be
answered by this study. We may have set the cut-off
points for intervention for the flow velocity ratio too
low, thus revising an unnecessarily high number of
veins.22
There is, however, no generally accepted criteria
for defining a hemodynamically significant AVF. We
used the ratio between the flow velocity immediately
proximal and distal to the AVF. If it can be assumed
that the diameter of the vein is equal proximal and
distal to the AVF, a flow velocity reduction distal to
the AVF would indicate that blood is shunted to the
deep venous system. Whether or not this also leads to
a decrease in peripheral perfusion is uncertain. It
seems logical that residual AVF impair distal flow
when flow velocity is reduced distal to the AVF.
It could be argued, however, that most residual
AVF did not influence peripheral perfusion in spite
of the reduction in flow velocity distal to the AVF
seen by the nonexistent influence on ABI.23-25 This
was only seen, however, in one patient in whom the
postoperative ABI was found to be unexpectedly low
in spite of a patent graft. The important issue there-
fore is to select a suitable cut-off limit. In our study,
we used any flow velocity reduction seen as a ratio of
more than 1 as the criteria for a significant AVF.
Under the condition that ABI is not affected, the
limit could perhaps be set at 2 to 2.5 without com-
promising patency in accordance with findings
regarding vein graft stenoses.26
A prospective study that investigates this ques-
tion has been designed at our institution. Until the
results are available, our data support the position
that only AVF that affect in situ bypass graft hemo-
dynamics, seen as a decrease in flow velocity distal to
the AVF, should be occluded. The indication for lig-
ature is strengthened when the postoperative ABI is
low in spite of a patent graft. Small AVF identified
after operation, which do not influence the hemody-
namics of the bypass graft, will likely occlude during
the first postoperative year.
We thank Fleming Hansen, MD, Department of
Clinical Physiology, Malmö University Hospital, for valu-
able comments.
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Fig 1. Cumulative patency rates did not differ between the two groups. The 1-year cumulative pri-
mary patency rates were 68% for group 1 and 76% for group 2 (log-rank test, 0.71; degree of freedom
= 1; P = .40). The 1-year assisted primary patency rates were 68% for group 1 and 83% for group 2
(log-rank test, 1.69; degree of freedom = 1; P = .19).
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